|
US5852188A
(en)
|
1990-01-11 |
1998-12-22 |
Isis Pharmaceuticals, Inc. |
Oligonucleotides having chiral phosphorus linkages
|
|
DE59108644D1
(de)
|
1990-07-02 |
1997-05-07 |
Hoechst Ag |
Oligonucleotid-analoge mit terminalen 3'-3'-bzw. 5'-5'-Internucleotidverknüpfungen
|
|
US5512668A
(en)
|
1991-03-06 |
1996-04-30 |
Polish Academy Of Sciences |
Solid phase oligonucleotide synthesis using phospholane intermediates
|
|
TW323284B
(enExample)
|
1992-03-23 |
1997-12-21 |
Novartis Ag |
|
|
US5216168A
(en)
|
1992-04-01 |
1993-06-01 |
G. D. Searle & Co. |
2- and 3- amino and azido derivatives of 1,5-iminosugars
|
|
US6242589B1
(en)
|
1998-07-14 |
2001-06-05 |
Isis Pharmaceuticals, Inc. |
Phosphorothioate oligonucleotides having modified internucleoside linkages
|
|
US6617442B1
(en)
|
1999-09-30 |
2003-09-09 |
Isis Pharmaceuticals, Inc. |
Human Rnase H1 and oligonucleotide compositions thereof
|
|
US20030138797A1
(en)
|
2001-06-29 |
2003-07-24 |
Micrologix Biotech Inc. |
Nucleic acid-based compounds
|
|
WO2003025139A2
(en)
|
2001-09-17 |
2003-03-27 |
Mayo Foundation For Medical Education And Research |
Cobalamin mediated delivery of nucleic acids, analogs and derivatives thereof
|
|
JP4348044B2
(ja)
|
2002-02-12 |
2009-10-21 |
株式会社キラルジェン |
立体規則性の高いジヌクレオシドホスホロチオエートの製造法
|
|
US8232383B2
(en)
|
2002-02-20 |
2012-07-31 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
|
|
EP2333062A1
(en)
|
2002-07-10 |
2011-06-15 |
Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. |
RNA-interference by single-stranded RNA molecules
|
|
US8729036B2
(en)
|
2002-08-07 |
2014-05-20 |
University Of Massachusetts |
Compositions for RNA interference and methods of use thereof
|
|
AR040996A1
(es)
|
2002-08-19 |
2005-04-27 |
Coley Pharm Group Inc |
Acidos nucleicos inmunoestimuladores
|
|
US7598227B2
(en)
|
2003-04-16 |
2009-10-06 |
Isis Pharmaceuticals Inc. |
Modulation of apolipoprotein C-III expression
|
|
JP2005089441A
(ja)
|
2003-08-08 |
2005-04-07 |
Toudai Tlo Ltd |
立体規則性の高いリン原子修飾ヌクレオチド類縁体の製造法
|
|
JP4616175B2
(ja)
|
2003-09-02 |
2011-01-19 |
株式会社キラルジェン |
５’−ホスフィチル化モノマーおよびｈ−ホスホネートオリゴヌクレオチド誘導体の製造方法
|
|
WO2005023828A1
(ja)
|
2003-09-02 |
2005-03-17 |
Takeshi Wada |
リボヌクレオチド又はリボヌクレオチド誘導体の製造方法
|
|
MY145571A
(en)
|
2003-12-19 |
2012-02-29 |
Ciba Holding Inc |
Fluorocarbon terminated oligo-and poly-carbonates as surface modifiers
|
|
WO2005070859A1
(ja)
|
2004-01-27 |
2005-08-04 |
Takeshi Wada |
フルオラス担体およびそれを用いたオリゴヌクレオチド誘導体の製造方法
|
|
WO2005085272A1
(ja)
|
2004-03-05 |
2005-09-15 |
Takeshi Wada |
ボラノホスフェートモノマーおよびそれを用いたオリゴヌクレオチド誘導体の製造方法
|
|
JP4865544B2
(ja)
|
2004-03-25 |
2012-02-01 |
株式会社キラルジェン |
立体規則性の高いリボヌクレオチド類縁体及びデオキシリボヌクレオチド類縁体の製造法
|
|
USRE47769E1
(en)
|
2004-06-28 |
2019-12-17 |
The University Of Western Australia |
Antisense oligonucleotides for inducing exon skipping and methods of use thereof
|
|
US7427675B2
(en)
|
2004-08-23 |
2008-09-23 |
Isis Pharmaceuticals, Inc. |
Compounds and methods for the characterization of oligonucleotides
|
|
DE502005008153D1
(de)
|
2005-11-23 |
2009-10-29 |
Roche Diagnostics Gmbh |
Polynukleotid mit Phosphatmimetikum
|
|
JP5184621B2
(ja)
|
2007-04-18 |
2013-04-17 |
エフ．ホフマン−ラ ロシュ アーゲー |
α−リン酸擬似体を有するヌクレオチド
|
|
HUE028662T2
(en)
|
2007-10-26 |
2016-12-28 |
Academisch Ziekenhuis Leiden |
Preparations and methods for controlling muscle disorders
|
|
WO2009124238A1
(en)
|
2008-04-04 |
2009-10-08 |
Isis Pharmaceuticals, Inc. |
Oligomeric compounds comprising neutrally linked terminal bicyclic nucleosides
|
|
ES2638448T3
(es)
|
2008-04-15 |
2017-10-20 |
Protiva Biotherapeutics Inc. |
Novedosas formulaciones de lípidos para la administración de ácidos nucleicos
|
|
US8324366B2
(en)
|
2008-04-29 |
2012-12-04 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for delivering RNAI using lipoproteins
|
|
EP2358398A2
(en)
|
2008-10-24 |
2011-08-24 |
Isis Pharmaceuticals, Inc. |
Oligomeric compounds and methods
|
|
US20120059045A1
(en)
|
2008-10-24 |
2012-03-08 |
Isis Pharmaceuticals, Inc. |
Methods of using oligomeric compounds comprising 2'-substituted nucleosides
|
|
PT2344637E
(pt)
|
2008-10-27 |
2015-03-23 |
Academisch Ziekenhuis Leiden |
Métodos e meios para o salto eficiente do exão 45 no pré-mrna de distrofia muscular de duchenne
|
|
SG171914A1
(en)
|
2008-12-02 |
2011-07-28 |
Chiralgen Ltd |
Method for the synthesis of phosphorus atom modified nucleic acids
|
|
CA2750561C
(en)
|
2009-01-26 |
2017-10-10 |
Protiva Biotherapeutics, Inc. |
Compositions and methods for silencing apolipoprotein c-iii expression
|
|
IN2012DN00720A
(enExample)
|
2009-07-06 |
2015-06-19 |
Ontorii Inc |
|
|
WO2011005860A2
(en)
|
2009-07-07 |
2011-01-13 |
Alnylam Pharmaceuticals, Inc. |
5' phosphate mimics
|
|
WO2011034072A1
(ja)
|
2009-09-16 |
2011-03-24 |
株式会社キラルジェン |
Rna及びその誘導体合成のための新規保護基
|
|
WO2011109427A2
(en)
|
2010-03-01 |
2011-09-09 |
Alnylam Pharmaceuticals, Inc. |
Improving the biological activity of sirna through modulation of its thermodynamic profile
|
|
JP2011184318A
(ja)
|
2010-03-05 |
2011-09-22 |
Univ Of Tokyo |
リボヌクレシドｈ−ボラノホスホネート
|
|
WO2011108682A1
(ja)
|
2010-03-05 |
2011-09-09 |
国立大学法人 東京大学 |
リボヌクレオシドホスホロチオエートの製造方法
|
|
US20130156845A1
(en)
|
2010-04-29 |
2013-06-20 |
Alnylam Pharmaceuticals, Inc. |
Lipid formulated single stranded rna
|
|
TWI541024B
(zh)
|
2010-09-01 |
2016-07-11 |
日本新藥股份有限公司 |
反義核酸
|
|
JP2013541334A
(ja)
|
2010-09-15 |
2013-11-14 |
アルニラム ファーマスーティカルズ インコーポレイテッド |
修飾されたｉＲＮＡ剤
|
|
WO2012039448A1
(ja)
|
2010-09-24 |
2012-03-29 |
株式会社キラルジェン |
不斉補助基
|
|
EP2647644B1
(en)
|
2010-11-30 |
2020-09-09 |
Wave Life Sciences Japan, Inc. |
2'-o-modified rna
|
|
KR20190062511A
(ko)
|
2011-04-27 |
2019-06-05 |
아이오니스 파마수티컬즈, 인코포레이티드 |
아포지방단백질 ｃｉｉｉ （ａｐｏｃｉｉｉ） 발현의 조정
|
|
RU2631805C2
(ru)
|
2011-06-21 |
2017-09-26 |
Элнилэм Фармасьютикалз, Инк. |
Композиции и способы ингибирования экспрессии генов аполипопротеина с-iii (арос3)
|
|
EP2731434A4
(en)
|
2011-07-13 |
2014-12-31 |
Merck Sharp & Dohme |
5'-SUBSTITUTED NUCLEOSIDE DERIVATIVES AND METHOD FOR THEIR USE FOR THE TREATMENT OF VIRUS DISEASES
|
|
MX347361B
(es)
|
2011-07-19 |
2017-04-12 |
Wave Life Sciences Ltd |
Metodos para la sintesis de acidos nucleicos funcionalizados.
|
|
JPWO2013089157A1
(ja)
|
2011-12-12 |
2015-04-27 |
独立行政法人国立循環器病研究センター |
オリゴヌクレオチド、およびオリゴヌクレオチドを有効成分として含有する高脂血症治療剤
|
|
CN111893117B
(zh)
*
|
2012-01-27 |
2024-06-04 |
比奥马林技术公司 |
治疗杜兴型肌营养不良症和贝克型肌营养不良症的具有改善特性的rna调节性寡核苷酸
|
|
RU2674600C2
(ru)
|
2012-07-03 |
2018-12-11 |
Просенса Текнолоджиз Б.В. |
Олигонуклеотид для лечения пациентов с мышечной дистрофией
|
|
EP2872147B1
(en)
|
2012-07-13 |
2022-12-21 |
Wave Life Sciences Ltd. |
Method for making chiral oligonucleotides
|
|
EP2872485B1
(en)
|
2012-07-13 |
2020-12-16 |
Wave Life Sciences Ltd. |
Asymmetric auxiliary group
|
|
AU2013287630B2
(en)
|
2012-07-13 |
2017-05-25 |
Shin Nippon Biomedical Laboratories, Ltd. |
Chiral nucleic acid adjuvant
|
|
RU2015119411A
(ru)
|
2012-11-15 |
2017-01-10 |
Рош Инновейшен Сентер Копенгаген А/С |
Конъюгаты антисмысловых соединений, направленные на аполипопротеин в
|
|
ES2680599T3
(es)
|
2013-02-14 |
2018-09-10 |
Ionis Pharmaceuticals, Inc. |
Modulación de la expresión de apolipoproteína C-III (ApoCIII) en poblaciones deficientes en lipoproteína lipasa (LPLD)
|
|
PL2992098T3
(pl)
|
2013-05-01 |
2019-09-30 |
Ionis Pharmaceuticals, Inc. |
Kompozycje i sposoby modulowania ekspresji hbv i ttr
|
|
JPWO2015108048A1
(ja)
|
2014-01-15 |
2017-03-23 |
株式会社新日本科学 |
抗腫瘍作用を有するキラル核酸アジュバンド及び抗腫瘍剤
|
|
EP3095460A4
(en)
|
2014-01-15 |
2017-08-23 |
Shin Nippon Biomedical Laboratories, Ltd. |
Chiral nucleic acid adjuvant having anti-allergic activity, and anti-allergic agent
|
|
US10144933B2
(en)
|
2014-01-15 |
2018-12-04 |
Shin Nippon Biomedical Laboratories, Ltd. |
Chiral nucleic acid adjuvant having immunity induction activity, and immunity induction activator
|
|
CN106068325B
(zh)
|
2014-01-16 |
2021-07-09 |
波涛生命科学有限公司 |
手性设计
|
|
EP3514234A1
(en)
|
2014-03-12 |
2019-07-24 |
Nippon Shinyaku Co., Ltd. |
Antisense nucleic acid
|
|
EP3137605B1
(en)
|
2014-05-01 |
2020-10-28 |
Ionis Pharmaceuticals, Inc. |
Compositions and methods for modulating angiopoietin-like 3 expression
|
|
RU2708237C2
(ru)
*
|
2014-08-22 |
2019-12-05 |
Общество с ограниченной ответственностью "НооГен" |
Модифицированные олигонуклеотиды и способ их получения
|
|
AU2015350120B2
(en)
|
2014-11-17 |
2021-05-27 |
Alnylam Pharmaceuticals, Inc. |
Apolipoprotein C3 (APOC3) iRNA compositions and methods of use thereof
|
|
CA2976445A1
(en)
|
2015-02-13 |
2016-08-18 |
Alnylam Pharmaceuticals, Inc. |
Patatin-like phospholipase domain containing 3 (pnpla3) irna compositions and methods of use thereof
|
|
DK3277814T3
(da)
|
2015-04-03 |
2020-08-24 |
Univ Massachusetts |
Oligonukleotidforbindelser til målretning mod huntingtin-mrna
|
|
MA43072A
(fr)
|
2015-07-22 |
2018-05-30 |
Wave Life Sciences Ltd |
Compositions d'oligonucléotides et procédés associés
|
|
EP3350328A1
(en)
|
2015-09-14 |
2018-07-25 |
Alnylam Pharmaceuticals, Inc. |
Polynucleotide agents targeting patatin-like phospholipase domain containing 3 (pnpla3) and methods of use thereof
|
|
JP7511326B2
(ja)
|
2015-10-09 |
2024-07-05 |
ウェイブ ライフ サイエンシズ リミテッド |
オリゴヌクレオチド組成物およびその方法
|
|
BR112018007066A2
(pt)
|
2015-10-09 |
2018-10-23 |
Sarepta Therapeutics Inc |
composições e métodos para tratamento da distrofia muscular de duchene e distúrbios relacionados
|
|
JP7749201B6
(ja)
|
2016-01-31 |
2025-10-21 |
ユニバーシティー オブ マサチューセッツ |
分岐オリゴヌクレオチド
|
|
MA43822A
(fr)
|
2016-03-13 |
2018-11-28 |
Wave Life Sciences Ltd |
Compositions et procédés de synthèse de phosphoramidite et d'oligonucléotides
|
|
MA45270A
(fr)
*
|
2016-05-04 |
2017-11-09 |
Wave Life Sciences Ltd |
Compositions d'oligonucléotides et procédés associés
|
|
MA45290A
(fr)
|
2016-05-04 |
2019-03-13 |
Wave Life Sciences Ltd |
Procédés et compositions d'agents biologiquement actifs
|
|
MA45183A
(fr)
|
2016-05-24 |
2019-04-10 |
Sarepta Therapeutics Inc |
Procédés de préparation d'oligomères morpholino de phosphorodiamidate
|
|
JP2019520339A
(ja)
|
2016-06-03 |
2019-07-18 |
ウェイブ ライフ サイエンシズ リミテッドＷａｖｅ Ｌｉｆｅ Ｓｃｉｅｎｃｅｓ Ｌｔｄ． |
オリゴヌクレオチド、その組成物および方法
|
|
US20180028554A1
(en)
*
|
2016-07-05 |
2018-02-01 |
Biomarin Technologies B.V. |
Oligomers Having Bicyclic Scaffold Moeities
|
|
WO2018014042A1
(en)
*
|
2016-07-15 |
2018-01-18 |
Ionis Pharmaceuticals, Inc. |
Compounds and methods for modulation of dystrophin transcript
|
|
WO2018022473A1
(en)
|
2016-07-25 |
2018-02-01 |
Wave Life Sciences Ltd. |
Phasing
|
|
RU2016138168A
(ru)
|
2016-09-26 |
2018-03-29 |
Оксфордский Университет |
Аналоги олигонуклеотидов как средства коррекции сплайсинга для лечения мышечной дистрофии дюшена
|
|
US11873316B2
(en)
|
2016-11-23 |
2024-01-16 |
Wave Life Sciences Ltd. |
Compositions and methods for phosphoramidite and oligonucleotide synthesis
|
|
RU2740501C2
(ru)
|
2017-02-21 |
2021-01-14 |
Федеральное государственное бюджетное учреждение науки Институт химической биологии и фундаментальной медицины Сибирского отделения Российской академии наук (ИХБФМ СО РАН) |
МОДИФИЦИРОВАННЫЕ ОЛИГОНУКЛЕОТИДЫ, АКТИВИРУЮЩИЕ РНКазу Н
|
|
US11603532B2
(en)
|
2017-06-02 |
2023-03-14 |
Wave Life Sciences Ltd. |
Oligonucleotide compositions and methods of use thereof
|
|
CN120330183A
(zh)
|
2017-06-02 |
2025-07-18 |
波涛生命科学有限公司 |
寡核苷酸组合物及其使用方法
|
|
TW201904587A
(zh)
|
2017-06-02 |
2019-02-01 |
新加坡商波濤生命科學有限公司 |
寡核苷酸組合物及其使用方法
|
|
CN111051281A
(zh)
|
2017-06-21 |
2020-04-21 |
波涛生命科学有限公司 |
用于合成的化合物、组合物和方法
|
|
EP3645544B1
(en)
|
2017-06-28 |
2023-05-10 |
Roche Innovation Center Copenhagen A/S |
Multiple coupling&oxidation method
|
|
JP2020534253A
(ja)
|
2017-08-08 |
2020-11-26 |
ウェーブ ライフ サイエンシーズ リミテッド |
オリゴヌクレオチド組成物及びその方法
|
|
KR20200052369A
(ko)
|
2017-09-18 |
2020-05-14 |
웨이브 라이프 사이언시스 리미티드 |
올리고뉴클레오티드 제조 기술
|
|
MX2020003596A
(es)
|
2017-10-04 |
2020-07-22 |
Avidity Biosciences Inc |
Composiciones de acido nucleico-polipeptido y usos de las mismos.
|
|
US11596646B2
(en)
|
2017-10-12 |
2023-03-07 |
Wave Life Sciences Ltd. |
Oligonucleotide compositions and methods thereof
|
|
AR113490A1
(es)
|
2017-12-12 |
2020-05-06 |
Amgen Inc |
CONSTRUCCIONES DE ARNi PARA INHIBIR LA EXPRESIÓN DE PNPLA3 Y MÉTODOS DE USO DE LAS MISMAS
|
|
EP3775203A4
(en)
|
2018-04-12 |
2022-03-30 |
Wave Life Sciences Ltd. |
OLIGONUCLEOTIDE COMPOSITIONS AND METHODS OF USE THEREOF
|
|
AU2019265904A1
(en)
|
2018-05-11 |
2020-11-12 |
Wave Life Sciences Ltd. |
Oligonucleotide compositions and methods of use thereof
|
|
TWI869213B
(zh)
|
2018-09-19 |
2025-01-01 |
美商Ionis製藥公司 |
Pnpla3表現之調節劑
|
|
SG11202105626TA
(en)
|
2018-12-06 |
2021-06-29 |
Wave Life Sciences Ltd |
Oligonucleotide compositions and methods thereof
|
|
CA3126845A1
(en)
|
2019-02-01 |
2020-08-06 |
Wave Life Sciences Ltd. |
Oligonucleotide compositions and methods thereof
|
|
US20230089442A1
(en)
|
2019-03-20 |
2023-03-23 |
Pachamuthu Kandasamy |
Technologies useful for oligonucleotide preparation
|
|
US20220307019A1
(en)
|
2019-03-25 |
2022-09-29 |
National University Corporation Tokyo Medical And Dental University |
Double-stranded nucleic acid complex and use thereof
|
|
US20250051778A1
(en)
|
2019-04-25 |
2025-02-13 |
Wave Life Sciences Ltd. |
Oligonucleotide compositions and methods of use thereof
|
|
US20230145795A1
(en)
|
2019-04-25 |
2023-05-11 |
Wave Life Sciences Ltd. |
Oligonucleotide compositions and methods of use thereof
|
|
CN114502177A
(zh)
|
2019-05-09 |
2022-05-13 |
波涛生命科学有限公司 |
寡核苷酸组合物及其使用方法
|
|
JP7766589B2
(ja)
|
2019-10-06 |
2025-11-10 |
ウェイブ ライフ サイエンシズ リミテッド |
オリゴヌクレオチド組成物及びその使用方法
|
|
US20240175016A1
(en)
|
2019-10-06 |
2024-05-30 |
Wave Life Sciences Ltd. |
Oligonucleotide compositions and methods of use thereof
|
|
WO2021126734A1
(en)
|
2019-12-16 |
2021-06-24 |
Alnylam Pharmaceuticals, Inc. |
Patatin-like phospholipase domain containing 3 (pnpla3) irna compositions and methods of use thereof
|
|
EP4114939A4
(en)
|
2020-03-01 |
2024-03-20 |
Wave Life Sciences Ltd. |
OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF
|
|
CN115397436B
(zh)
|
2020-03-26 |
2025-07-08 |
箭头药业股份有限公司 |
用于抑制PNPLA3表达的RNAi剂、其药物组合物和使用方法
|
|
EP4153747A2
(en)
|
2020-05-22 |
2023-03-29 |
Wave Life Sciences Ltd. |
Double stranded oligonucleotide compositions and methods relating thereto
|
|
WO2021237223A1
(en)
|
2020-05-22 |
2021-11-25 |
Wave Life Sciences Ltd. |
Oligonucleotide compositions and methods thereof
|
|
WO2022046667A1
(en)
|
2020-08-24 |
2022-03-03 |
Wave Life Sciences Ltd. |
Cells and non-human animals engineered to express adar1 and uses thereof
|
|
WO2022046723A1
(en)
|
2020-08-24 |
2022-03-03 |
Wave Life Sciences Ltd. |
Immunoassays for detecting wild type huntingtin protein and methods of treatment employing such immunoassays
|
|
EP4217363A4
(en)
|
2020-09-24 |
2024-09-25 |
Mayo Foundation for Medical Education and Research |
Screening platforms
|
|
EP4221720A4
(en)
|
2020-10-02 |
2024-11-13 |
Ionis Pharmaceuticals, Inc. |
METHODS FOR REDUCING APOCIII EXPRESSION
|
|
CN116507724A
(zh)
|
2020-11-08 |
2023-07-28 |
波涛生命科学有限公司 |
寡核苷酸组合物及其方法
|
|
KR20230118716A
(ko)
|
2020-11-08 |
2023-08-11 |
웨이브 라이프 사이언시스 리미티드 |
올리고뉴클레오티드 조성물 및 이의 방법
|
|
EP4404942A2
(en)
|
2021-09-26 |
2024-07-31 |
Wave Life Sciences Ltd. |
Compositions for editing mecp2 transcripts and methods thereof
|
|
IL311625A
(en)
|
2021-09-26 |
2024-05-01 |
Wave Life Sciences Ltd |
Oligonucleotide compositions and methods thereof
|
|
CA3236136A1
(en)
|
2021-10-27 |
2023-05-04 |
Wave Life Sciences Ltd. |
Oligonucleotide compositions and methods of use thereof
|
|
EP4422645A4
(en)
|
2021-10-27 |
2025-12-03 |
Wave Life Sciences Ltd |
OLIGONUCLEOTID COMPOSITIONS AND THEIR METHODS OF USE
|
|
WO2023154528A1
(en)
|
2022-02-11 |
2023-08-17 |
Wave Life Sciences Ltd. |
Stereoselective technologies for chiral compounds
|
|
CN119137134A
(zh)
|
2022-03-02 |
2024-12-13 |
波涛生命科学有限公司 |
寡核苷酸组合物及其用于外显子跳跃的方法
|
|
US20250262235A1
(en)
|
2022-04-15 |
2025-08-21 |
Wave Life Sciences Ltd. |
Oligonucleotide compositions and methods relating thereto
|
|
US20250302995A1
(en)
|
2022-05-12 |
2025-10-02 |
Chikdu Shakti Shivalila |
Oligonucleotide compositions and methods thereof
|
|
CN120476205A
(zh)
|
2022-08-11 |
2025-08-12 |
波涛生命科学有限公司 |
寡核苷酸组合物及其方法
|
|
WO2025030155A1
(en)
|
2023-08-03 |
2025-02-06 |
Wave Life Sciences Ltd. |
Oligonucleotide compositions and methods thereof
|